checkAd

     230  0 Kommentare Oracle Health Sciences Adds 93 Emerging Biopharmaceutical Customers

    REDWOOD SHORES, CA--(Marketwired - Sep 29, 2015) -  Oracle (NYSE: ORCL)

    Emerging biopharmaceutical organizations face a growing number of regulatory requirements and, due to increased competition1, acute pressure to speed time to market. Today, Oracle Health Sciences announced that 93 of these emerging biopharma organizations worldwide have become new customers in the past year, adopting Oracle Health Sciences solutions to succeed in this rapidly evolving market and deliver drugs to patients faster.

    Biopharmaceutical organizations, including sponsors such as Accera and NewLink Genetics and contract research organizations (CROs) FMD K&L and 4C Pharma Solutions, selected Oracle Health Sciences solutions to manage their end-to-end clinical trial processes, boost clinical development productivity, facilitate compliance, and build scalable, affordable platforms for growth.

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Amazon.com Inc.!
    Long
    173,95€
    Basispreis
    1,18
    Ask
    × 14,66
    Hebel
    Short
    198,64€
    Basispreis
    1,21
    Ask
    × 14,29
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    "Oracle has long been a trusted partner working alongside smaller, emerging firms by developing innovative solutions to help them grow," said Steve Rosenberg, senior vice president and general manager, Oracle Health Sciences. "Our industry-leading clinical development, management, and safety solutions deploy rapidly and scale on demand, empowering emerging biopharmas to optimize clinical productivity, focus resources on innovation, and manage critical regulatory requirements with confidence."

    With the robust functionality of the Oracle Health Sciences suite of industry-leading cloud solutions2 such as Oracle Health Sciences InForm, Oracle Health Sciences IRT, Oracle Argus, Oracle's Siebel Clinical Trial Management System, and Oracle Health Sciences ClearTrial Plan and Source Enterprise Edition Cloud Service, these emerging organizations can now optimize productivity and navigate complex regulatory compliance requirements with ease.

    FMD K&L adopted Oracle Health Sciences InForm to help ensure data accuracy and efficiencies.

    "We are dedicated to providing high-quality results to get our clients' drug or medical products approved quickly," said Dr. Xin Ke, president, FMD K&L. "Oracle Health Sciences InForm is a proven, industry-leading clinical data management system that enables us to raise the standard of excellence through accuracy and consistency on a continuous basis. Additionally, the ability to collaborate with Oracle on developing industry standards and implementation best practices has been invaluable in improving the quality and efficiency of our services."

    Seite 1 von 3




    Verfasst von Marketwired
    Oracle Health Sciences Adds 93 Emerging Biopharmaceutical Customers REDWOOD SHORES, CA--(Marketwired - Sep 29, 2015) -  Oracle (NYSE: ORCL) Emerging biopharmaceutical organizations face a growing number of regulatory requirements and, due to increased competition1, acute pressure to speed time to market. …

    Schreibe Deinen Kommentar

    Disclaimer